|
1
|
World Health Organization (WHO):
International agency for research on cancer. GLOBOCAN 2020:
Oesophagus cancer fact sheet. WHO, Geneva, 2020.
|
|
2
|
Codipilly DC and Wang KK: Squamous cell
carcinoma of the esophagus. Gastroenterol Clin North Am.
51:457–484. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Morgan E, Soerjomataram I, Rumgay H,
Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J and Arnold
M: The global landscape of esophageal squamous cell carcinoma and
esophageal adenocarcinoma incidence and mortality in 2020 and
projections to 2040: New estimates from GLOBOCAN 2020.
Gastroenterology. 163:649–658.e2. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kauppila JH, Mattsson F, Brusselaers N and
Lagergren J: Prognosis of oesophageal adenocarcinoma and squamous
cell carcinoma following surgery and no surgery in a nationwide
Swedish cohort study. BMJ Open. 8(e021495)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang Z, Shao C, Wang Y, Duan H, Pan M,
Zhao J, Wang J, Ma Z, Li X and Yan X: Efficacy and safety of
neoadjuvant immunotherapy in surgically resectable esophageal
cancer: A systematic review and meta-analysis. Int J Surg.
104(106767)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Deng J, Wang C, Xiang M, Liu F, Liu Y and
Zhao K: Meta-analysis of postoperative efficacy in patients
receiving chemoradiotherapy followed by surgery for resectable
esophageal carcinoma. Diagn Pathol. 9(151)2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang Z, Sun S, Li K, Huang C, Liu X, Zhang
G and Li X: Feasibility analysis of combined surgery for esophageal
cancer. World J Surg Oncol. 21(41)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Launois B, Delarue D, Campion JP and
Kerbaol M: Preoperative radiotherapy for carcinoma of the
esophagus. Surg Gynecol Obstet. 153:690–692. 1981.PubMed/NCBI
|
|
10
|
van Hagen P, Hulshof MCCM, van Lanschot
JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel
DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Preoperative chemoradiotherapy for esophageal or junctional cancer.
N Engl J Med. 366:2074–2084. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhao S, Qi W and Chen J: Role of a
multidisciplinary team in administering radiotherapy for esophageal
cancer. BMC Cancer. 20(974)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chinese Society of Clinical Oncology
(CSCO): Guidelines of Chinese society of clinical oncology (CSCO)
Esophageal cancer. CSCO, 2023.
|
|
13
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato
H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al:
Esophageal cancer practice guidelines 2017 edited by the Japan
esophageal society: Part 2. Esophagus. 16:25–43. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ajani JA, D'Amico TA, Bentrem DJ, Cooke D,
Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, et al:
Esophageal and Esophagogastric Junction Cancers, Version 2.2023,
NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc
Netw. 21:393–422. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li C, Zhao S, Zheng Y, Han Y, Chen X,
Cheng Z, Wu Y, Feng X, Qi W, Chen K, et al: Preoperative
pembrolizumab combined with chemoradiotherapy for oesophageal
squamous cell carcinoma (PALACE-1). Eur J Cancer. 144:232–241.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Le Prise E, Etienne PL, Meunier B, Maddern
G, Ben Hassel M, Gedouin D, Boutin D, Campion JP and Launois B: A
randomized study of chemotherapy, radiation therapy, and surgery
versus surgery for localized squamous cell carcinoma of the
esophagus. Cancer. 73:1779–1784. 1994.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Almhanna K, Shridhar R and Meredith KL:
Neoadjuvant or adjuvant therapy for resectable esophageal cancer:
Is there a standard of care? Cancer Control. 20:89–96.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Schlag PM: Randomized trial of
preoperative chemotherapy for squamous cell cancer of the
esophagus. The chirurgische arbeitsgemeinschaft fuer onkologie der
deutschen gesellschaft fuer chirurgie study group. Arch Surg.
127:1446–1450. 1992.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kelsen DP, Ginsberg R, Pajak TF, Sheahan
DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W,
et al: Chemotherapy followed by surgery compared with surgery alone
for localized esophageal cancer. N Engl J Med. 339:1979–1984.
1998.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kelsen DP, Winter KA, Gunderson LL,
Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth
JA, et al: Long-term results of RTOG trial 8911 (USA Intergroup
113): A random assignment trial comparison of chemotherapy followed
by surgery compared with surgery alone for esophageal cancer. J
Clin Oncol. 25:3719–3725. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M (eds): Esophagus. In: American
Joint Committee on Cancer (AJCC) cancer staging manual. 6th
edition. New York, NY: Springer, pp167-178, 2002.
|
|
22
|
Allum WH, Stenning SP, Bancewicz J, Clark
PI and Langley RE: Long-term results of a randomized trial of
surgery with or without preoperative chemotherapy in esophageal
cancer. J Clin Oncol. 27:5062–5067. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Loc NVV, Vuong NL, Trung LV and Trung TT:
Effect of time to minimally invasive esophagectomy after
neoadjuvant chemotherapy for esophageal squamous cell carcinoma. J
Gastrointest Cancer. 1–12. 2023.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
24
|
Depypere L: The effect of time interval on
esophagectomy after neoadjuvant treatment. Ann Transl Med.
4(117)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tiesi G, Park W, Gunder M, Rubio G, Berger
M, Ardalan B, Livingstone A and Franceschi D: Long-term survival
based on pathologic response to neoadjuvant therapy in esophageal
cancer. J Surg Res. 216:65–72. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nakamura K, Kato K, Igaki H, Ito Y,
Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, et
al: Three-arm phase III trial comparing cisplatin plus 5-FU (CF)
versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy
with CF (CF-RT) as preoperative therapy for locally advanced
esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol.
43:752–755. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Matsuda S, Kitagawa Y, Takemura R, Okui J,
Okamura A, Kawakubo H, Muto M, Kakeji Y, Takeuchi H, Watanabe M and
Doki Y: Real-world evaluation of the efficacy of neoadjuvant DCF
Over CF in esophageal squamous cell carcinoma: Propensity
score-matched analysis from 85 authorized institutes for esophageal
cancer in Japan. Ann Surg. 278:e35–e42. 2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ojima T, Nakamori M, Nakamura M, Katsuda
M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Iwahashi M
and Yamaue H: Neoadjuvant chemotherapy with divided-dose docetaxel,
cisplatin and fluorouracil for patients with squamous cell
carcinoma of the esophagus. Anticancer Res. 36:829–834.
2016.PubMed/NCBI
|
|
29
|
Sobin LH, Gospodarowicz MK and Wittekind C
(eds): TNM classification of malignant tumors. 7th edition. Oxford:
Wiley-Blackwell, 2010.
|
|
30
|
Hayata K, Ojima T, Nakamori M, Nakamura M,
Katsuda M, Kitadani J, Takeuchi A, Tabata H, Maruoka S and Yamaue
H: Neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for
resectable advanced esophageal cancer. Anticancer Res.
38:5267–5273. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Medical Research Council Oesophageal
Cancer Working Group. Surgical resection with or without
preoperative chemotherapy in oesophageal cancer: A randomised
controlled trial. Lancet. 359:1727–1733. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chan KKW, Saluja R, Delos Santos K, Lien
K, Shah K, Cramarossa G, Zhu X and Wong RKS: Neoadjuvant treatments
for locally advanced, resectable esophageal cancer: A network
meta-analysis. Int J Cancer. 143:430–437. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abouarab MH, Salem IL, Degheidy MM, Henn
D, Hirche C, Eweida A, Uhl M, Kneser U and Kremer T: Therapeutic
options and postoperative wound complications after extremity soft
tissue sarcoma resection and postoperative external beam
radiotherapy. Int Wound J. 15:148–158. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Feeney G, Sehgal R, Sheehan M, Hogan A,
Regan M, Joyce M and Kerin M: Neoadjuvant radiotherapy for rectal
cancer management. World J Gastroenterol. 25:4850–4869.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bahadoer RR, Dijkstra EA, van Etten B,
Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID,
Beets-Tan RGH, Blomqvist LK, et al: Short-course radiotherapy
followed by chemotherapy before total mesorectal excision (TME)
versus preoperative chemoradiotherapy, TME, and optional adjuvant
chemotherapy in locally advanced rectal cancer (RAPIDO): A
randomised, open-label, phase 3 trial. Lancet Oncol. 22:29–42.
2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Choi YS, Sin JI, Kim JH, Ye GW, Shin IH
and Lee TS: Survival benefits of neoadjuvant chemotherapy followed
by radical surgery versus radiotherapy in locally advanced
chemoresistant cervical cancer. J Korean Med Sci. 21:683–689.
2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ
and Zhang DW: Randomized clinical trial on the combination of
preoperative irradiation and surgery in the treatment of esophageal
carcinoma: Report on 206 patients. Int J Radiat Oncol Biol Phys.
16:325–327. 1989.PubMed/NCBI
|
|
38
|
Nygaard K, Hagen S, Hansen HS, Hatlevoll
R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E,
Rosengren B, et al: Pre-operative radiotherapy prolongs survival in
operable esophageal carcinoma: A randomized, multicenter study of
pre-operative radiotherapy and chemotherapy. The second
Scandinavian trial in esophageal cancer. World J Surg.
16:1104–1110. 1992.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Huang Y, Wang H, Luo G, Zhang Y, Wang L
and Li K: A systematic review and network meta-analysis of
neoadjuvant therapy combined with surgery for patients with
resectable esophageal squamous cell carcinoma. Int J Surg.
38:41–47. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lehrer E, Geyer S, Goodrich A, Ilson DH,
Noonan A, Dumane VA and Goodman KA: Impact of lung and heart
radiation dose during preoperative chemoradiation on overall
survival (OS) in esophageal cancer (EC)-secondary analysis of CALGB
80803 (Alliance). Iscahn school of medicine at mount sinai. ASTRO.
114 (Suppl)(S13)2022.
|
|
41
|
Sobin LH and Fleming ID: TNM
classification of malignant tumors. 5th edition. John Wiley and
Sons, New York, NY, 1997.
|
|
42
|
Mariette C, Dahan L, Mornex F, Maillard E,
Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, et
al: Surgery alone versus chemoradiotherapy followed by surgery for
stage I and II esophageal cancer: Final analysis of randomized
controlled phase III trial FFCD 9901. J Clin Oncol. 32:2416–2422.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant
chemoradiotherapy followed by surgery versus surgery alone for
locally advanced squamous cell carcinoma of the esophagus
(NEOCRTEC5010): A phase III Multicenter, Randomized, open-label
clinical trial. J Clin Oncol. 36:2796–2803. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Long-term efficacy of
neoadjuvant chemoradiotherapy plus surgery for the treatment of
locally advanced esophageal squamous cell carcinoma: The
NEOCRTEC5010 randomized clinical trial. JAMA Surg. 156:721–729.
2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Guo X, Wang Z, Yang H, Mao T, Chen Y, Zhu
C, Yu Z, Han Y, Mao W, Xiang J, et al: Impact of lymph node
dissection on survival after neoadjuvant chemoradiotherapy for
locally advanced esophageal squamous cell carcinoma: From the
results of NEOCRTEC5010, a randomized multicenter study. Ann Surg.
277:259–266. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Klevebro F, Alexandersson von Döbeln G,
Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen
NI, Lind P, Tsai JA, et al: A randomized clinical trial of
neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for
cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol.
27:660–667. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Li J: Neoadjuvant chemoradiotherapy vs
neoadjuvant chemotherapy for the treatment of esophageal squamous
cell carcinoma: A stabilized inverse probability of treatment
weighting analysis. ASTRO. 114 (Suppl):E162–E163. 2022.
|
|
48
|
Hamai Y, Hihara J, Taomoto J, Yamakita I,
Ibuki Y and Okada M: Effects of neoadjuvant chemoradiotherapy on
postoperative morbidity and mortality associated with esophageal
cancer. Dis Esophagus. 28:358–364. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sathornviriyapong S, Matsuda A, Miyashita
M, Matsumoto S, Sakurazawa N, Kawano Y, Yamada M and Uchida E:
Impact of neoadjuvant chemoradiation on short-term outcomes for
esophageal squamous cell carcinoma patients: A meta-analysis. Ann
Surg Oncol. 23:3632–3640. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Straatman J, van der Wielen N, Cuesta MA,
Daams F, Roig Garcia J, Bonavina L, Rosman C, van Berge Henegouwen
MI, Gisbertz SS and van der Peet DL: Minimally invasive versus open
esophageal resection: Three-year follow-up of the previously
reported randomized controlled trial: The TIME trial. Ann Surg.
266:232–236. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rice TW, Chen LQ, Hofstetter WL, Smithers
BM, Rusch VW, Wijnhoven BP, Chen KL, Davies AR, D'Journo XB, Kesler
KA, et al: Worldwide Esophageal Cancer Collaboration: Pathologic
staging data. Dis Esophagus. 29:724–733. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang H, Tang H, Fang Y, Tan L, Yin J, Shen
Y, Zeng Z, Zhu J, Hou Y, Du M, et al: Morbidity and mortality of
patients who underwent minimally invasive esophagectomy after
neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for
locally advanced esophageal squamous cell carcinoma: A randomized
clinical trial. JAMA Surg. 156:444–451. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Al-Kaabi A, van der Post RS, van der Werf
LR, Wijnhoven BPL, Rosman C, Hulshof MCCM, van Laarhoven HWM,
Verhoeven RHA and Siersema PD: Impact of pathological tumor
response after CROSS neoadjuvant chemoradiotherapy followed by
surgery on long-term outcome of esophageal cancer: A
population-based study. Acta Oncol. 60:497–504. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Greally M, Chou JF, Molena D, Rusch VW,
Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, et
al: Positron-emission tomography scan-directed chemoradiation for
esophageal squamous cell carcinoma: No benefit for a change in
chemotherapy in positron-emission tomography nonresponders. J
Thorac Oncol. 14:540–546. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Li CC, Chen CY, Chou YH, Huang CJ, Ku HY,
Lin YC and Chien CR: High vs low radiotherapy dose in locally
advanced esophageal squamous cell carcinoma patients treated with
neoadjuvant concurrent chemoradiotherapy: An endemic area
population-based study. Discov Oncol. 13(130)2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ruhstaller T, Widmer L, Schuller JC, Roth
A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC,
BalmerMajno S, et al: Multicenter phase II trial of preoperative
induction chemotherapy followed by chemoradiation with docetaxel
and cisplatin for locally advanced esophageal carcinoma (SAKK
75/02). Ann Oncol. 20:1522–1528. 2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Satake H, Tahara M, Mochizuki S, Kato K,
Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, et al: A
prospective, multicenter phase I/II study of induction chemotherapy
with docetaxel, cisplatin and fluorouracil (DCF) followed by
chemoradiotherapy in patients with unresectable locally advanced
esophageal carcinoma. Cancer Chemother Pharmacol. 78:91–99.
2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Ajani JA, Xiao L, Roth JA, Hofstetter WL,
Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, et al:
A phase II randomized trial of induction chemotherapy versus no
induction chemotherapy followed by preoperative chemoradiation in
patients with esophageal cancer. Ann Oncol. 24:2844–2849.
2013.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Harada G, Bonadio RRDCC, de Araújo FCC,
Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR and de
Castria TB: Induction chemotherapy for locally advanced esophageal
cancer. J Gastrointest Cancer. 51:498–505. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Gao LR, Li C, Han W, Ni W, Deng W, Li Y
and Xiao Z: Survival benefit of surgery in patients with clinical
T4 esophageal cancer responded to neoadjuvant
chemoradiotherapy/radiotherapy. ASTRO. 114
(Suppl)(E159)2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Emens LA and Middleton G: The interplay of
immunotherapy and chemotherapy: Harnessing potential synergies.
Cancer Immunol Res. 3:436–443. 2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Yu WD, Sun G, Li J, Xu J and Wang X:
Mechanisms and therapeutic potentials of cancer immunotherapy in
combination with radiotherapy and/or chemotherapy. Cancer Lett.
452:66–70. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Yap TA, Parkes EE, Peng W, Moyers JT,
Curran MA and Tawbi HA: Development of immunotherapy combination
strategies in cancer. Cancer Discov. 11:1368–1397. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y,
Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al: Camrelizumab versus
investigator's choice of chemotherapy as second-line therapy for
advanced or metastatic oesophageal squamous cell carcinoma
(ESCORT): A multicentre, randomised, open-label, phase 3 study.
Lancet Oncol. 21:832–842. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Yang W, Xing X, Yeung SJ, Wang S, Chen W,
Bao Y, Wang F, Feng S, Peng F, Wang X, et al: Neoadjuvant
programmed cell death 1 blockade combined with chemotherapy for
resectable esophageal squamous cell carcinoma. J Immunother Cancer.
10(e003497)2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Liu J, Li J, Lin W, Shao D, Depypere L,
Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab
plus chemotherapy for resectable, locally advanced esophageal
squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2
study. Int J Cancer. 151:128–137. 2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H,
Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm,
phase II trial of camrelizumab and chemotherapy as neoadjuvant
treatment for locally advanced esophageal squamous cell carcinoma.
J Immunother Cancer. 10(e004291)2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G,
Zhong R, You Z, Wang R, Lu Y, et al: Evaluation of clinical and
safety outcomes of neoadjuvant immunotherapy combined with
chemotherapy for patients with resectable esophageal cancer: A
systematic review and meta-analysis. JAMA Netw Open.
5(e2239778)2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Liu Y, Bao Y, Men Y, Wang Y and Hui Z:
Efficacy and safety of neoadjuvant immunotherapy combined with
chemoradiotherapy vs combined with chemotherapy in esophageal
cancer: A systematic review and meta-analysis. ASTRO. 114
(Suppl):E163–E164. 2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hong HE, Kim HR, Park SY, Kim DJ, Lee CG,
Cho J, Kim JH, Kim HR, Kim YH, Park SR and Cho BC: A phase II trial
of preoperative chemoradiotherapy and pembrolizumab for locally
advanced esophageal squamous cell carcinoma (ESCC). J Clin Oncol.
37 (Suppl)(S4027)2019.
|
|
72
|
van den Ende T, de Clercq NC, van Berge
Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL,
Schokker S, Dings MPG, Bergman JJGHM, et al: Neoadjuvant
chemoradiotherapy combined with atezolizumab for resectable
esophageal adenocarcinoma: A single-arm phase II feasibility trial
(PERFECT). Clin Cancer Res. 27:3351–3359. 2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Brenner B, Purim O, Gordon N, Goshen-Lago
T, Idelevich E, Kashtan H, Menasherov N, Fenig E, Sulkes A and
Kundel Y: The addition of cetuximab to preoperative
chemoradiotherapy for locally advanced esophageal squamous cell
carcinoma is associated with high rate of long term survival:
Mature results from a prospective phase Ib/II trial. Radiother
Oncol. 134:74–80. 2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ruhstaller T, Pless M, Dietrich D,
Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM,
Rauch D, Gautschi O, et al: Cetuximab in combination with
chemoradiotherapy before surgery in patients with resectable,
locally advanced esophageal carcinoma: A prospective, multicenter
phase IB/II trial (SAKK 75/06). J Clin Oncol. 29:626–631.
2011.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Ruhstaller T, Thuss-Patience P, Hayoz S,
Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W,
Eisterer W, Hawle H, et al: Neoadjuvant chemotherapy followed by
chemoradiation and surgery with and without cetuximab in patients
with resectable esophageal cancer: A randomized, open-label, phase
III trial (SAKK 75/08). Ann Oncol. 29:1386–1393. 2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ye P: To explore the effect of the number
of administration cycles of camrelizumab combined with chemotherapy
on neoadjuvant therapy for stage IIB-IVA thoracic resectable
esophageal cancer. Registration number: ChiCTR2200061139. Date of
Registration: 2022-06-15.
|
|
77
|
Yi Z: Real-World clinical study of
cindimizumab combined with chemotherapy in neoadjuvant treatment of
resectable esophageal cancer. Registration number:
ChiCTR2100050561. Date of Registration: 2021-08-28.
|
